The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheterdirected thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome.
D espite the use of anticoagulant therapy, the post-thrombotic syndrome develops within 2 years in approximately half of patients with proximal deep-vein thrombosis. [1] [2] [3] [4] The post-thrombotic syndrome commonly causes chronic limb pain and swelling and can progress to cause major disability, leg ulcers, and impaired quality of life. 5, 6 Small randomized trials have suggested that active removal of acute thrombus may preserve venous function and prevent the post-thrombotic syndrome (the "openvein hypothesis"). 3, 7, 8 Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis") is the delivery of a fibrinolytic drug into the thrombus with concomitant thrombus aspiration or maceration. 9 The objective of pharmacomechanical thrombolysis is to diminish the thrombus burden by means of low-dose fibrinolysis and mechanical therapy, thereby reducing the risk of the post-thrombotic syndrome while minimizing the risk of bleeding. [10] [11] [12] [13] We performed the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial to determine whether pharmacomechanical thrombolysis prevents the post-thrombotic syndrome in patients with proximal deep-vein thrombosis.
Me thods

Trial Organization
We conducted a phase 3, multicenter, randomized, open-label, assessor-blinded, controlled clinical trial sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health. Boston Scientific and Covidien (now Medtronic) provided supplemental funding. The trial drug and additional funding were provided by Genentech. Compression stockings were donated by BSN Medical. These companies played no role in the design or conduct of the trial or in the analysis or reporting of the data.
The trial was approved by the institutional review boards at all participating centers. The steering committee and site investigators were responsible for the design 14 and conduct of the trial, respectively. The contract research organization Inclinix provided guidance to support participant-recruitment efforts, and data analyses were conducted by the trial statistical staff (see the Supplementary Appendix, available with the full text of this article at NEJM.org). The steering committee vouches for the accuracy and completeness of the data and the analyses and for the fidelity of the trial to the protocol, which is available at NEJM.org.
Patient Population
Patients with symptomatic proximal deep-vein thrombosis involving the femoral, common femoral, or iliac vein (with or without other involved ipsilateral veins) were enrolled at 56 clinical centers in the United States. Patients were excluded if they were younger than 16 or older than 75 years of age, were pregnant, had had symptoms for more than 14 days, were at high bleeding risk, had active cancer, had established post-thrombotic syndrome, or had had ipsilateral deep-vein thrombosis in the previous 2 years. The full list of eligibility criteria, investigators, and sites is provided in the Supplementary Appendix. All the patients provided written informed consent.
Randomization
Patients were randomly assigned in a 1:1 ratio to the pharmacomechanical-thrombolysis group or the control group (no procedural intervention) with the use of a Web-based central randomization system that ensured concealment of the treatment assignments. Randomization was stratified according to clinical center and thrombus extent (i.e., whether thrombosis involved the common femoral or iliac vein [iliofemoral deep-vein thrombosis] or not [femoropopliteal deep-vein thrombosis]). The randomization sequence, with varying block sizes, was computer-generated by an independent statistician.
Treatment and Outcome Assessments
Patients in each treatment group received initial and long-term anticoagulant therapy consistent with published guidelines, including the option of rivaroxaban when it became available, and were provided sized-to-fit, knee-high, elastic compression stockings providing 30 to 40 mm Hg of pressure (BSN Medical) at the 10-day follow-up visit and every 6 months.
15,16 Pharmacomechanical catheter-directed thrombolysis was performed in a manner consistent with published guidelines by board-certified physicians whose credentials were approved by the trial leadership. 14, 17, 18 A detailed description of these methods is provided in the Supplementary Appendix.
Recombinant tissue plasminogen activator (rt-PA) (alteplase [Activase, Genentech] at a dose T h e ne w e ngl a nd jou r na l o f m e dicine of <35 mg) was delivered into the thrombus by one of three methods. If the popliteal vein was occluded or the inferior vena cava was involved, physicians were required to use "infusion-first" therapy, which started with rt-PA infusion through a multi-sidehole catheter of the physician's choice for no longer than 30 hours. For the remaining patients, physicians were required to first attempt single-session thrombus removal with rapid delivery of rt-PA through the AngioJet Rheolytic Thrombectomy System (Boston Scientific) or the Trellis Peripheral Infusion System (Covidien) and then to infuse rt-PA for no longer than 24 hours if residual thrombus was present.
After the initial delivery of rt-PA, physicians could use balloon maceration, catheter aspiration, thrombectomy with the use of the AngioJet or Trellis system, percutaneous transluminal balloon venoplasty, stent placement (iliac or common femoral vein), or a combination of procedures to clear residual thrombus and treat obstructive lesions. 17, 18 Stenting was encouraged for lesions that were causing 50% or greater narrowing of the diameter of the vein, robust collateral filling, or a mean pressure gradient of more than 2 mm Hg. Treatment was discontinued when there was at least 90% thrombus removal with restoration of flow or when there was a serious complication.
The international normalized ratio was required to be 1.6 or lower at the start of pharmacomechanical thrombolysis. During the procedure, patients received twice-daily subcutaneous injections of low-molecular-weight heparin in therapeutic doses or unfractionated heparin infusions (with the dose reduced to 6 to 12 units per kilogram of body weight per hour [maximum, 1000 units per hour] during rt-PA infusions). Additional unfractionated heparin boluses (up to 50 units per kilogram) were given during the procedure at the physician's discretion.
Trial outcomes were assessed at 10 and 30 days and 6, 12, 18, and 24 months after randomization. The clinical personnel who performed assessments of efficacy outcomes and the adjudicators of safety and efficacy outcomes were unaware of the treatment assignments.
Primary Efficacy Outcome
Development of the post-thrombotic syndrome, the primary efficacy outcome, was defined as a Villalta score of 5 or higher or an ulcer in the leg with the index deep-vein thrombosis, at any time between the 6-month follow-up visit and the 24-month follow-up visit. 19, 20 The Villalta scale ranges from 0 to 33, with higher scores indicating more severe post-thrombotic syndrome (details are provided in the Supplementary Appendix). Patients were also counted as having the post-thrombotic syndrome if they underwent an unplanned endovascular procedure to treat severe venous symptoms beyond 6 months after randomization, unless a Villalta score within the previous 4 weeks was lower than 5.
Secondary Efficacy and Safety Outcomes
The occurrence of the post-thrombotic syndrome at 6, 12, 18, and 24 months was counted if the Villalta score at that visit was 5 or higher. The severity of the post-thrombotic syndrome was evaluated at 6, 12, 18 and 24 months with the use of the Villalta scale and the Venous Clinical Severity Score 21 (scores range from 0 to 27, with higher scores indicating more severe postthrombotic syndrome). The proportion of patients with moderate-to-severe post-thrombotic syndrome (Villalta score, ≥10) was also assessed.
A major non-post-thrombotic syndrome treatment failure was assessed when any of three events occurred in the index leg: an unplanned endovascular procedure to treat severe venous symptoms within 6 months, venous gangrene within 6 months, or an amputation within 24 months. The combined outcome of the postthrombotic syndrome or major non-post-thrombotic syndrome treatment failure was also assessed.
Patient-reported health-related quality of life at baseline and 24 months was assessed with the use of the generic Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) 22 and the venous disease-specific Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure. 23 Leg pain and leg swelling at baseline, 10 days, and 30 days were assessed with the use of a 7-point Likert pain scale (with higher scores indicating more severe pain) 24 and by measuring calf circumference, respectively.
In the pharmacomechanical-thrombolysis group, thrombus removal was quantified by independent central readers who scored venograms obtained before and after the procedure, using the proximal-vein components of the Marder score. 25 The modified Marder score ranges from
Pharmacomechanical Thrombolysis for Deep-Vein Thrombosis 0 to 24, with 0 representing no thrombus and 24 representing complete thrombosis. Safety outcomes included bleeding, recurrent venous thromboembolism, and death, which were reported throughout follow-up and summarized through 10 days and 24 months. 26 A detailed description of all trial outcomes is provided in the Supplementary Appendix.
Statistical Analysis
We estimated that the post-thrombotic syndrome would develop in 30% of the patients in the control group between 6 and 24 months 1,27-29 and hypothesized that pharmacomechanical thrombolysis would reduce this percentage to 20% or lower. [30] [31] [32] [33] Assuming a 10% loss to follow-up, we calculated that 692 patients would be required in order for the trial to have 80% power to detect the hypothesized treatment effect at a two-sided α of 0.05.
Two types of analyses were performed: a modified intention-to-treat analysis that included all patients who underwent randomization except those who did not have deep-vein thrombosis at enrollment, and a per-protocol analysis that excluded patients who, within 7 days after randomization, were randomly assigned to receive pharmacomechanical thrombolysis but did not receive it or who were randomly assigned to the control group but had skin puncture for pharmacomechanical thrombolysis or any thrombolytic therapy.
The primary analysis was a modified intentionto-treat analysis that compared the cumulative proportion of patients who had development of the post-thrombotic syndrome within 24 months between the treatment groups with the use of the Cochran-Mantel-Haenszel test with adjustment for the two stratification variables. A two-sided P value of 0.05 or lower was considered to indicate statistical significance. The treatment effects are summarized with the use of stratum-adjusted risk ratios and their corresponding 95% confidence intervals. To account for the missing assessments during follow-up, a sensitivity analysis with multiple imputation, under the assumption that data were missing at random, was conducted on the Cochran-Mantel-Haenszel risk-ratio estimates with the use of prespecified auxiliary variables (age, sex, body-mass index, extent of deep-vein thrombosis, the maximum Villalta score observed at assessments from 6 to 24 months, and available Villalta scores at baseline, 10 days, or 30 days). Details are provided in the Supplementary Appendix.
Prespecified secondary analyses included a perprotocol analysis of the primary outcome and modified intention-to-treat and per-protocol analyses of each of the secondary efficacy outcomes. Stratum-adjusted Cochran-Mantel-Haenszel tests were used for the analysis of each of the categorical secondary outcomes and safety outcomes. The mean Villalta and Venous Clinical Severity Score assessments at each visit were estimated with the use of piecewise linear-regression growth-curve models with adjustment for strata and prespecified baseline covariates (age, sex, body-mass index, and Villalta score). Changes from baseline to 24 months in quality-of-life scores and from baseline to 10 and 30 days in leg-pain scores and calf circumferences were compared between the two treatment groups by means of linear regression with adjustment for strata. To account for multiple testing, a twosided P value of 0.01 or lower was considered to indicate statistical significance for the secondary efficacy analyses. A two-sided P value of 0.05 or lower was considered to indicate statistical significance for the safety analyses.
R esult s
Characteristics of the Patients at Baseline
From December 2009 through December 2014, a total of 692 patients underwent randomization (337 to the pharmacomechanical-thrombolysis group and 355 to the control group) (Fig. 1) . One patient who was assigned to the pharmacomechanical-thrombolysis group was excluded from all analyses; on review of prerandomization assessments by personnel who were unaware of the treatment assignments, this patient was found not to have a qualifying deep-vein thrombosis. The baseline characteristics of the patients were similar in the treatment groups (Table 1, and  Table S2 in the Supplementary Appendix).
Protocol and Treatment Adherence
Within 7 days after randomization, 5 patients who had been assigned to the control group underwent pharmacomechanical thrombolysis, and 11 patients who had been assigned to the pharmacomechanical-thrombolysis group did not undergo the procedure. These patients were excluded from the per-protocol analysis. The use of anticoagula-T h e ne w e ngl a nd jou r na l o f m e dicine tion and compression stockings and the elements of pharmacomechanical thrombolysis are summarized in Table 2 . The mean duration of anticoagulation before the first permanent cessation was similar in the two treatment groups (median days to stopping, 211 days in the pharmacomechanical-thrombolysis group and 231 days in the control group; P = 0.16) ( Table 2 ). Pharmacomechanical thrombolysis was performed at a median of 1 day after randomization. The mean degree of thrombus removal was 76% (mean preprocedure Marder score, 11.4; mean postprocedure Marder score, 2.7; change, −8.7; 95% confidence interval [CI], −8.1 to −9.4; P<0.001).
Post-Thrombotic Syndrome
In the primary analysis, the post-thrombotic syndrome developed over the 24-month period in 157 of 336 patients (47%) assigned to the pharmacomechanical-thrombolysis group and in 171 of 355 patients (48%) assigned to the control group (risk ratio, 0.96; 95% CI, 0.82 to 1.11; P = 0.56) ( Table 3 ). The findings were similar in a per-protocol analysis (151 of 325 patients who underwent pharmacomechanical thrombolysis and 169 of 350 who did not undergo pharmacomechanical thrombolysis; risk ratio, 0.94; 95% CI, 0.81 to 1.10) and in a sensitivity analysis with multiple imputation (risk ratio, 0.89; 95% CI, 0.78 to 1.02) (Tables S3 and S4 in the Supplementary Appendix). The results were similar in prespecified subgroups (Fig. S1 in the Supplementary Appendix), except for a suggestion that patients 65 years of age or older were less likely to benefit from pharmacomechanical thrombolysis than younger patients (P = 0.04 for the interaction).
Secondary Efficacy Outcomes
There was no significant between-group difference in the percentage of patients who had major non-post-thrombotic syndrome treatment failure or overall treatment failure (P≤0.01 was considered to indicate statistical significance for the secondary efficacy analyses) ( Table 3) . Moderate-to-severe post-thrombotic syndrome (Villalta score, ≥10) occurred in 18% of the patients in the pharmacomechanical thrombolysis group and 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P = 0.04). The severity of the post-thrombotic syndrome, as assessed by the mean Villalta score and mean Venous Clinical Severity Score, was significantly lower in the pharmacomechanical-thrombolysis group than in the control group at all visits between 6 and 24 months (P≤0.01 for the between-group comparison at each time point, with the exception of the comparison of the Venous Clinical Severity Score at 24 months, for which P=0.03) ( Table 4) . Over the 24-month period, there was no signifi- The reasons for the exclusion of patients before randomization are shown in Table S1 in the Supplementary Appendix. Randomization was stratified according to clinical center and extent of deep-vein thrombosis. Two patients (one in each treatment group) missed all four assessments for the postthrombotic syndrome (PTS) because they died before 6 months. LEP denotes late endovascular procedure. * IQR denotes interquartile range. † Race was reported by the patient. ‡ Body-mass index is the weight in kilograms divided by the square of the height in meters. § The Villalta scale is an assessment of five patient-reported symptoms (cramps, itching, pins and needles, leg heaviness, and pain) and six signs reported by clinicians who were unaware of the treatment assignments (pretibial edema, skin induration, hyperpigmentation, venous ectasia, redness, and pain during calf compression), scored on a 4-point scale (a score of 0 denotes none or minimal, 1 mild, 2 moderate, and 3 severe) and summed into a total score for each leg; a leg with an ulcer was assigned a minimum score of 15 points. Total scores range from 0 to 33, with higher scores indicating more severe post-thrombotic syndrome; a score of 0 to 4 denotes none or minimal, 5 to 9 mild, 10 to 14 moderate, and 15 or higher severe. Two patients in the control group were not assessed. ¶ Patients could be included in more than one category. ‖ Anticoagulant therapy that was given after the diagnosis of deep-vein thrombosis and before randomization is shown. cant between-group difference in the change in venous disease-specific quality of life (P = 0.08) or general quality of life (P = 0.37). The mean decreases in leg pain from baseline in the pharmaco mechanical-thrombolysis group and the control group were 1.62 and 1.29 Likert points at 10 days, respectively (P = 0.02), and 2.17 and 1.83 Likert points at 30 days, respectively (P = 0.03). For leg circumference, a decrease of 0.26 cm and an increase of 0.27 cm from baseline at 10 days occurred in the pharmacomechanical-thrombo lysis group and the control group, respectively (P = 0.02), and decreases from baseline of 0.74 cm and 0.28 cm had occurred at 30 days, respectively (P = 0.05). The results of the per-protocol analyses were similar to those of the modified intention-to-treat analyses (Tables  S5 and S6 in the Supplementary Appendix).
Safety Outcomes
Major bleeding within 10 days occurred in 6 patients (1.7%) assigned to the pharmacomechanicalthrombolysis group, as compared with 1 patient (0.3%) assigned to the control group (P = 0.049) ( Table 3) . Details of the bleeding events are shown in Table S7 in the Supplementary Appendix. Recurrent venous thromboembolism within 24 months occurred in 42 patients (12%) assigned to the pharmacomechanical-thrombolysis group (including 1 fatal pulmonary embolism at 6 months) and in 30 patients (8%) assigned to the control group (P = 0.09). Of the 15 deaths that occurred (7 in the pharmacomechanical thrombolysis group and 8 in the control group), none occurred within 10 days after randomization (Table 3, and Table S8 in the Supplementary Appendix). 
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Discussion
In this trial, pharmacomechanical thrombolysis did not prevent the post-thrombotic syndrome in patients with acute proximal deep-vein thrombosis; this finding persisted in per-protocol analyses and was consistent across all prespecified subgroups. In the pharmacomechanicalthrombolysis group, there were more early major bleeds than in the control group, but less major bleeding (1.7% of patients, with no fatal or intracranial bleeds) occurred in association with the procedure than in past studies of thrombolysis for deep-vein thrombosis. 3, 7, 18, [34] [35] [36] In the recent CAVENT (Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis) trial, catheter-directed thrombolysis reduced the risk of the post-thrombotic syndrome over periods of 2 and 5 years. 3, 34 Our trial, for uncertain reasons, did not confirm these findings. Differences between the two trials include the larger size of our trial (692 vs. 209 * For the secondary efficacy analyses, a P value of 0.01 or lower was considered to indicate statistical significance. † Mean scores, standard errors, and between-group differences were estimated with the use of growth-curve models and piecewise linear regression with adjustment for the extent of deep-vein thrombosis and clinical center and for baseline covariates (age, sex, body-mass index, and Villalta score). ‡ The Venous Clinical Severity Score (VCSS) ranges from 0 to 27, with higher scores indicating more severe post-thrombotic syndrome. § The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) includes a physical component score (PCS) and a mental component score (MCS). Each score ranges from 0 to 100, with higher scores indicating better quality of life. A difference of 3 to 4 points is considered clinically meaningful. ¶ Mean changes in scores, standard errors, and between-group differences were estimated with the use of multiple linear regression with adjustment for the extent of deep-vein thrombosis and clinical center. ‖ The Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) measure includes an overall score and a symptom-specific score. Each score ranges from 0 to 100, with higher sores indicating better quality of life. A difference of 3 to 4 points is considered clinically meaningful. ** The patient-reported severity of pain in the index leg was measured on a Likert scale. Scores range from 0 to 7, with higher scores indicating more severe pain. † † Leg circumference was measured at 10 cm below the tibial tuberosity of the index leg. T h e ne w e ngl a nd jou r na l o f m e dicine patients), its geographic and demographic scope (56 U.S. centers vs. 4 Norwegian centers), and our greater use of mechanical therapies versus the longer rt-PA infusions used in the CAVENT trial. Inadequate thrombus removal is unlikely to explain the failure of pharmacomechanical thrombolysis to prevent the post-thrombotic syndrome in our trial, since venography showed effective thrombus removal. Standard care for deep-vein thrombosis did not substantially differ between the two treatment groups and would not explain the observed lack of a beneficial effect of pharmacomechanical thrombolysis in preventing the post-thrombotic syndrome.
Our trial had several limitations. There was a substantial number of missing assessments of the post-thrombotic syndrome. As expected, there were occasional missed visits among patients who returned for follow-up, which were balanced between the treatment groups. However, among the 80 patients with no post-thrombotic syndrome assessments, two thirds were in the control group, which is likely to have resulted in an underestimate of the treatment effect. Although the sensitivity analysis conducted with the use of methods to impute assessments of the postthrombotic syndrome in these patients yielded findings similar to those in the primary analysis, the extent of incomplete follow-up is still a limitation of the trial.
A large number of patients had to be screened in order to enroll our target sample; this largely reflects the exclusion of patients who would not receive pharmacomechanical thrombolysis in clinical practice (e.g., patients with a high bleeding risk), but it could reduce the generalizability of the trial. The trial was medium-sized, but given the risks of pharmacomechanical thrombolysis, it was unlikely to miss a treatment effect of sufficient size to influence clinical practice. However, the trial had limited power to examine treatment effects within subgroups. Although many elements of pharmacomechanical thrombolysis were standardized, there was variation in how the procedure was performed, in order to accommodate patient-specific differences and physician preferences. We did not randomly assign patients to specific treatment methods, which precluded a direct comparison of outcomes among the methods. Finally, most patients received warfarin; although direct oral anticoagulants are now frequently used, this change should not have affected the rates of the post-thrombotic syndrome, since both types of anticoagulation are similarly effective at preventing recurrent deepvein thrombosis. 15, 37 Because the post-thrombotic syndrome varies in its clinical manifestations, we evaluated its presence and severity in complementary ways. Assessments made with the use of the Villalta scale and the Venous Clinical Severity Score were consistent in suggesting that pharmacomechanical thrombolysis reduced the severity of the post-thrombotic syndrome, which raises the possibility that the etiologic factors that predispose patients to the development of the post-thrombotic syndrome may differ at least partly from those that determine progression to advanced post-thrombotic syndrome. Further study of the open-vein hypothesis may help to define the pathophysiological basis of the post-thrombotic syndrome and identify opportunities to reduce progression or alleviate disabling symptoms.
In conclusion, among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding.
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